Glaxo Smith Kline
Glaxo Smith Kline operates in various business sectors.
Glaxo Smith Kline (BIOC) - Net Assets
Latest net assets as of : EGP- EGP
Based on the latest financial reports, Glaxo Smith Kline (BIOC) has net assets worth EGP- EGP as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (EGP-) and total liabilities (EGP-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | EGP- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Glaxo Smith Kline - Net Assets Trend (None–None)
This chart illustrates how Glaxo Smith Kline's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Glaxo Smith Kline (None–None)
The table below shows the annual net assets of Glaxo Smith Kline from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to Glaxo Smith Kline's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Glaxo Smith Kline Competitors by Market Cap
The table below lists competitors of Glaxo Smith Kline ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ENGIE Energia Peru S.A.
LIM:ENGIEC1
|
$11.41K |
|
TAYLOR WIMPEY
BE:TWW
|
$11.42K |
|
National Refinery Ltd
KAR:NRL
|
$11.44K |
|
236030
KO:236030
|
$11.44K |
|
POSTNL
HM:TNTC
|
$11.40K |
|
SCHUMAG (SCM.SG)
STU:SCM
|
$11.40K |
|
National Housing for Professional Syndicates
EGX:NHPS
|
$11.40K |
|
GLINTT-GLOBAL INT.
BE:PAJA
|
$11.39K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Glaxo Smith Kline's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Glaxo Smith Kline's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Glaxo Smith Kline utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares Glaxo Smith Kline's net assets metrics with peer companies in the same industry.
No peer company data available for comparison.